Expand RARE Menu
RARE MENU

RARE Latest Press Releases

-- February 24, 2025 --

Ultragenyx to Participate at Investor Conferences in March Globe Newswire 4:30 PM

-- February 19, 2025 --

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- February 18, 2025 --

Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) Globe Newswire 8:00 AM

-- February 13, 2025 --

Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update Globe Newswire 4:01 PM

-- February 6, 2025 --

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Globe Newswire 4:30 PM

-- February 5, 2025 --

Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS Globe Newswire 8:00 AM

-- January 17, 2025 --

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- January 12, 2025 --

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones Globe Newswire 11:00 AM

-- January 6, 2025 --

Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference Globe Newswire 4:30 PM

-- December 20, 2024 --

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- December 19, 2024 --

Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome Globe Newswire 4:05 PM
Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA) Globe Newswire 8:00 AM

-- November 26, 2024 --

Ultragenyx to Participate in Investor Conferences in December Globe Newswire 4:30 PM

-- November 20, 2024 --

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- November 9, 2024 --

Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science Summit Globe Newswire 10:30 AM

-- November 5, 2024 --

Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update Globe Newswire 4:01 PM

-- October 29, 2024 --

Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update Globe Newswire 4:05 PM

-- October 18, 2024 --

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- October 7, 2024 --

Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta Globe Newswire 8:00 AM